Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.49 |
| ▸ | CA2 | P00918 | 4/20 | 0.49 |
| ▸ | CA9 | Q16790 | 4/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13973059 | 0.85 | CA1 (0.49) | CA1CA2CA9CA14MEN1 | |
| SCHEMBL4421998 | 0.84 | CA1 (0.46) | CA1CA2CA9CA14MEN1 | |
| SCHEMBL4414695 | 0.81 | CA1 (0.49) | CA1CA2CA9CA14MEN1 | |
| SCHEMBL13972643 | 0.79 | MEN1 (0.64) | MEN1KMT2APOLBALDH1A1LMNA | |
| SCHEMBL4424375 | 0.78 | HTT (0.71) | KMT2ALMNAHTTNCOA1SMN1; SMN2 | |
| SCHEMBL4414414 | 0.74 | KMT2A (0.45) | MEN1KMT2AFKBP1ALMNAMAPT | |
| SCHEMBL14427607 | 0.72 | LMNA (0.69) | CA1CA2CA9CA14MEN1 | |
| SCHEMBL4418789 | 0.71 | VCAM1 (0.47) | CA1CA2CA9CA14MEN1 | |
| SCHEMBL16169931 | 0.69 | ACHE (0.73) | MEN1KMT2APOLBALDH1A1FKBP1A | |
| SCHEMBL4414803 | 0.69 | VCAM1 (0.41) | CA1CA2CA9CA14MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180021303-A1 | BKCA CHANNEL ACTIVATOR FOR TREATING MUSCULAR DISORDER | CANBEX THERAPEUTICS LTD (GB) | 2018-01-25 | — | — | US | disclosed |
| EP-1663983-B1 | N-SUBSTITUTED, 6,8-DIALKOXY-1,2,3,4-TETRAHYDRO-1H-ISOQUINOLINE AS POTASSIUM CHANNELS MODULATORS | 4SC AG (DE) | 2009-01-21 | — | — | EP | disclosed |
| US-20050070570-A1 | Novel potassium channels modulators | 4SC AG (DE) | 2005-03-31 | — | — | US | disclosed |
| EP-1489071-A1 | N-substituted, 3,4-dihydro-1H-isoquinoline as potassium channels modulators | 4SC AG (DE) | 2004-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180021303-A1 | BKCA CHANNEL ACTIVATOR FOR TREATING MUSCULAR DISORDER | KCNMA1, KCNMB1, KCNA1 | CA1 3947/4885CA2 1222/4885CA9 3760/4885 |
| US-20050070570-A1 | Novel potassium channels modulators | HCN4, KCNA4, KCNN4 | CA1 2370/4885CA2 335/4885CA9 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.